Clinical Trials Tracker

The program at a glance

Total TRIUMPH Phase 3 enrollment: approximately 5,800 participants. See the full clinical trials deep dive for each trial's design, endpoints, and citations.

2026 readout calendar

• Reported. TRIUMPH-4 (Dec 2025), TRANSCEND-T2D-1 (Mar 2026), and the pivotal TRIUMPH-1 (May 21, 2026) have all read out.
• Still expected in 2026. TRIUMPH-2 (obesity + T2D) and TRIUMPH-3 (CV disease) results remain outstanding; TRIUMPH-3 has completed primary data collection.
• 2027+. TRIUMPH-5 (head-to-head vs tirzepatide, NCT06662383) and TRIUMPH-Outcomes (CV/kidney CVOT, NCT06383390) are multi-year; earliest reads from 2027+.

How to participate

TRIUMPH-5 (head-to-head vs tirzepatide) and TRIUMPH-Outcomes (CV/kidney endpoints, ~10,000 participants) are both active, not recruiting — closed to new participants. Two studies are still open: TRIUMPH-7 (NCT07035093), for obesity or overweight with chronic low back pain, and the Phase 3 multi-agent MASLD master protocol (NCT07165028), which studies several drugs rather than retatrutide alone. Always re-check status before applying:

• How to sign up for a retatrutide clinical trial
• NCT07165028 — MASLD master protocol (recruiting)
• Lilly Trial Guide
• ClinicalTrials.gov — live retatrutide search

FDA timeline

The FDA filing trigger was the TRIUMPH-1 primary readout, which reported in May 2026. Retatrutide remains investigational; no BLA submission or FDA decision date has been confirmed by Lilly or the FDA. See the FDA approval timeline article for the full scenario analysis.